{
  "id": 16594123,
  "title": "Breakfast News: Science Strikes Back at Cancer",
  "url": "https://urgent.news/2026/10/26/breakfast-news-science-strikes-back-at-cancer",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-26T11:30:02.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/breakfast-news/2026/10/26/breakfast-news-science-strikes-back-at-cancer/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "The European Society for Medical Oncology (ESMO) Congress is currently ongoing in Madrid. This major cancer conference, running until October 27, has featured late-breaking trials displaying strong survival gains for patients. Emerging drug types like targeted antibody drugs, T-cell engagers, and vaccines have proven more effective than conventional treatments, both alone and in combination with traditional drugs. However, global stock markets remain under pressure. U.S. indexes, the S&P 500 and Nasdaq-100, have both seen declines of 0.47% and 0.71% respectively, marking the second consecutive week of losses. Artificial intelligence-driven spending concerns and increasing oil prices have been key drivers behind this sell-off. Meta Platforms (META), down 9.4% following earnings, led this market downturn. Meanwhile, Brent crude oil hit a six-month high of $116.72, buoyed by Middle East tensions. Despite these market challenges, certain stocks appear to present attractive investment opportunities. TransDigm Group (TDG) is one such example. With a five-year price prediction of $1,750, the stock has dropped 10% from its March recommendation and more than 30% from its July all-time high. Despite this, the company's sales have grown by 23% in the past quarter, and its full-year outlook remains optimistic. The market seems to underestimate the resilience of TransDigm's business, making this a potentially good time to invest.",
  "summary": "Cancer trial data shines at ESMO 2026, earnings flood after tough market week, and more…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}